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Abstract   
INTRODUCTION: We aimed to assess diagnostic accuracy of cerebrospinal fluid (CSF) YKL-40 
in discriminating: (i) Alzheimer’s disease (AD), cognitively healthy controls (HC), and 
frontotemporal dementia (FTD) in a purely clinical analysis (Level I), (ii) patients showing different 
AD pathologies from HC and FTD in an analysis independent of cognitive impairment severity, 
following an unbiased descriptive categorization based on CSF core biomarkers (Level II). 
METHODS: In a cross-sectional multi-center study, YKL-40 was compared among HC (n=21), 
mild cognitive impairment (MCI) (n=41), AD (n=35), FTD (n=9) (Level I); among HC (n=21), AD 
pathology (tau and amyloid-β) negative (n=15), tau-positive (n=15), amyloid-β-positive (n=13), AD 
pathology-positive (n=33), and FTD (n=9) (Level II). 
RESULTS: Level I: YKL-40 discriminated AD from HC and FTD with AUROCs=0.69, 0.71, 
respectively. Level II: YKL-40 discriminated tau-positive and AD pathology-positive patients from 
HC, and AD pathology-positive patients from FTD (AUROCs=0.76, 0.72, 0.73, respectively). 
DISCUSSION: YKL-40 provides fair performance in distinguishing tau-positive patients from HC. 
 
Key words: Alzheimer’s disease, Alzheimer’s disease pathophysiology, biomarkers, biomarker-
based diagnosis, cerebrospinal fluid, clinical diagnosis, dementia, diagnostic biomarkers, 
Frontotemporal dementia, mild cognitive impairment, neurodegeneration, neuroinflammation, 
YKL-40  
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Abbreviations: Alzheimer’s disease (AD); amyloid-β 1 to 42 (Aβ1-42); area under the receiver 
operating characteristic curve (AUROC); A/T/N system: A= Aβ, T= phospho-tau, N= total-tau; 
cerebrospinal fluid (CSF); cognitively healthy controls (HC); 18F-fluorodeoxyglucose-PET (18F-
FDG-PET); False Discovery Rate (FDR); fronto-temporal dementia (FTD); hyperphosphorylated 
tau (p-tau); Institute of Memory and Alzheimer’s Disease (IM2A); International working group-2 
(IWG-2); Kruskal-Wallis (KW); leave-one out cross validation (LOO-CV); mild cognitive 
impairment (MCI); Mental-State Examination (MMSE); National Institute on Aging–Alzheimer's 
Association (NIA-AA); National Institute of Neurological and Communicative Disorders and 
Stroke-Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA); pairwise 
multiple comparison of mean ranks (PMCMR); total tau (t-tau)  
 
1.1 INTRODUCTION  
Alzheimer’s disease (AD) is a clinically and neuropathologically heterogeneous and 
multifactorial disorder [1–3] whose primary pathophysiological hallmarks are amyloid plaques 
and neurofibrillary tangles depositions. However, in a majority of patients AD is combined with 
other types of pathology [4,5]. Currently, three cerebrospinal fluid (CSF) biomarkers have shown 
to be able to track the in vivo pathophysiological mechanisms of AD both in the prodromal and 
preclinical phases [6,7]. In particular, (I) the amyloid-β 1 to 42 (Aβ1-42) peptide is considered a 
marker of amyloid brain deposition, (II) total tau (t-tau) protein is thought to be a marker of 
neuronal injury (not exclusively due to AD) and (III) hyperphosphorylated tau (p-tau) protein is 
a marker reflecting deposition of neurofibrillary tangles [8]. Although neuroinflammation has 
been suggested to be a relevant pathophysiological mechanism in AD [1,9], a validated CSF 
biomarker to monitor neuroinflammation in AD is not available. So far, YKL-40, a glycoprotein 
belonging to the chitinase-like proteins group, represents a promising inflammatory marker for 
AD, although its exact pathophysiological role is unclear [10]. YKL-40 is a differentiation 
marker of macrophages [11–13] and is expressed in microglia and astroglia within the central 
nervous system [14]. Recently, elevated CSF concentrations of YKL-40 have been reported in 
AD compared with cognitively healthy controls (HC), also in its prodromal and preclinical 
phases [15–28].  
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The aim of this study was to assess the diagnostic accuracy of CSF YKL-40 in distinguishing 
among groups of cognitively impaired patients. In a first step (Level I), we tested the ability of 
YKL-40 in discriminating AD dementia patients from HC subjects and frontotemporal dementia  
cases (FTD), identified according to a purely clinical diagnostic approach. Successively, in a 
second level of analysis (Level II)  [4], we adopted an unbiased descriptive categorization system 
based on core biomarkers (A/T/N system: A= Aβ pathology, T= tau pathology, N= 
neurodegeneration) for characterizing AD pathology which was independent of the severity of 
cognitive impairment. In this context, we determined the diagnostic accuracy of YKL-40 in 
discriminating patients within the AD pathology spectrum (patients showing both decreased Aβ1-
42 and increased T-tau or P-tau CSF levels [7], patients which were only tau positive, patients 
which were only Aβ positive, patients negative to both biomarkers) from HC and FTD cases 
(Level II).  
 
2.1 METHODS 
 
2.1.1 Population 
Clinical and biological data from a convenience sample of 108 individuals (AD= 35, FTD= 9, 
MCI= 41, and cognitively HC= 23) were retrospectively collected in a multi-centre cross-
sectional study involving three independent academic AD research centres and memory clinics. 
Thirty-five subjects were recruited at the Institute of Memory and Alzheimer’s Disease (IM2A) 
at Pitié-Salpêtrière University Hospital in Paris (France); 57 at the German Centre for 
Neurodegenerative Diseases (DZNE) in Rostock (Germany); 16 at the Institute of Neuroscience 
and Physiology at Sahlgrenska University Hospital in Göteborg (Sweden).  
The study was conducted according to the provisions of the Declaration of Helsinki. All 
participants or their representatives gave written informed consent for the use of their clinical 
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data for research purposes and the local Ethical Committees at the respective universities 
approved the study.  
 
2.1.2 Patient stratification 
2.1.2.1 Level I (purely clinical diagnostic approach) 
The first group was composed of 23 cognitively HC. Two individuals from the Göteborg 
cohort resulted asymptomatic-at-risk of AD [7] or preclinical AD [29] because of high CSF t-tau 
concentrations and were thus excluded from further analyses. The second group included 41 
MCI patients [6]. The third group included 35 AD dementia patients [30]. Finally, the fourth 
group included 9 FTD patients [31] (Figure 1). The clinical diagnosis of AD dementia was 
performed according to the National Institute of Neurological and Communicative Disorders and 
Stroke-Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) consensus 
criteria [30]. The clinical diagnosis of MCI was made according to the MCI core clinical criteria 
[6]. The clinical diagnosis of FTD was made following the consensus on clinical diagnostic 
criteria of 1998 [31]. Cognitively HC were individuals who volunteered for a lumbar puncture; 
the inclusion criteria were the absence of history of neurological or psychiatric diseases and 
Mental-State Examination (MMSE) score between 27 and 30.  
 
2.1.2.2 Level II (unbiased categorization based on CSF core AD biomarker profiles)  
AD dementia and MCI patient categorization followed an unbiased biomarker-based 
descriptive classification system recently proposed by Jack and colleagues: the “A/T/N” system 
[4]. This classification considers 3 binary (i.e. positive or negative) categories: “A” referring to 
an amyloid biomarker (CSF Aβ1-42 or amyloid-PET), “T” to a tau pathology biomarker (CSF p-
tau or tau-PET), and “N” to a quantitative or topographic biomarker of neurodegeneration or 
neuronal injury (CSF t-tau, 18F-fluorodeoxyglucose-PET (18F-FDG-PET), or structural MRI). 
Since each individual score is displayed as an “A±/T±/N±” arrangement, eight different 
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categories are possible [4]. The A/T/N classification system is linked to the biomarker 
classification frameworks i.e. the International working group-2 (IWG-2) criteria [7] and the 
National Institute on Aging–Alzheimer's Association (NIA-AA) guidelines [5,29,30], and is able 
to chart both diagnostic classifications. The A/T/N system was utilized in a simplified version 
which employed only CSF markers and excluded the imaging-related ones (amyloid PET, tau 
PET, FDG-PET, or structural MR) to define 5 categories (groups) which were independent from 
severity of cognitive impairment:  
 Group 1 consisted of cognitively HCs (n= 21), a priori defined as both Aβ and tau negative 
[A-/T-/N-]; group 2 [A-/T-/N-] (n= 15), included 2 AD dementia and 13 MCI patients which 
were both Aβ and tau negative; group 3 [A-/T±/N+ or A-/T+/N±] (n= 15), encompassed 6 AD 
dementia and 9 MCI patients which were tau positive but Aβ negative; group 4 [A+/T-/N-] 
(n=13), contained 5 AD dementia and 8 MCI patients which were Aβ positive only; group 5 
[A+/T±/N+ or A+/T+/N±] (n=33) included 22 AD dementia patients in line with the IWG-2 
criteria [7] and the NIA-AA guidelines [32], and 11 prodromal AD [33] or MCI due to AD [6] 
cases, all of which were both Aβ and tau positive; group 6 comprised all FTD cases (n=9) 
including seven patients which were both Aβ1-42 and tau negative, one patient which was Aβ1-42 
negative and tau positive, and one which was patient Aβ1-42 positive and tau negative. According 
to the IWG-2 criteria this last participant should be defined as a case of FTD and not as a patient 
with a frontal variant of AD [7]. Of note, since the A/T/N system is not directly applicable to 
FTD, this last group was analysed exclusively in terms of clinical diagnosis (Figure 1).  
 
2.1.3 CSF sampling 
All CSF samples were collected in polypropylene tubes, centrifuged (1000 g, 10 minutes, 
+4°C (sample collected at IM2A laboratory for the Paris cohort), 1500 g, 10 minutes, +4°C 
(sample collected at DZNE laboratory for the Rostock cohort), 1800 g, 10 minutes, +4°C 
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(sample collected at Mölndal Clinical Neurochemistry Laboratory for the Göteborg cohort)), and 
the collected supernatant was stored at –80°C pending biochemical analysis.   
 
2.1.4 Immunoassays for core biomarkers 
All the core biomarkers (Aβ1-42, t-tau, and p-tau) were measured in the CSF of each subject. 
For the Paris cohort, CSF analyses were performed at the Laboratory of Biochemistry, Unit of 
Biochemistry of Neurometabolic diseases, Pitié-Salpêtrière University Hospital of Paris.  
For the Rostock cohort, CSF analyses were executed in two different units: the Institute of 
Clinical Chemistry and Laboratory Medicine, Rostock University Medical Centre, after 06/2012, 
and the Laboratory of Neurochemistry, Department of Neurology, Göttingen University Medical 
Centre, before 06/2012. 
For the Göteborg cohort, CSF analyses were executed at the Clinical Neurochemistry 
Laboratory at the Sahlgrenska University Hospital, Mölndal. 
T-tau was measured using a sandwich ELISA (INNOTEST hTAU-Ag, Fujirebio Europe, 
Gent, Belgium) specifically constructed to measure all tau isoforms irrespective of the 
phosphorylation status [34]. Tau phosphorylated at threonine 181 (p-tau181) was measured using 
a sandwich ELISA (INNOTEST Phospho-Tau[181P], Fujirebio Europe, Gent, Belgium) 
constructed to specifically measure tau protein phosphorylated at the amino acid threonine 181 
[35]. Aβ1-42 was measured using a sandwich ELISA (INNOTEST β-AMYLOID(1-42), Fujirebio 
Europe, Gent, Belgium), specifically constructed for the quantitative determination of Aβ1-42 
[36]. All analysis were performed by board-certified laboratory technicians blinded to clinical 
information. 
CSF biomarkers abnormalities were defined based on reference values currently used in each 
memory clinic: at IM2A in Paris, Aβ1-42 < 500 pg/mL, T-tau > 450 pg/mL, p-tau181 > 60 pg/mL; 
at DZNE in Rostock, Aβ1-42 < 567 pg/mL, T-tau > 512 pg/mL, p-tau181 > 66 pg/mL for the CSF 
samples measured before 06/2012 and Aβ1-42 < 450 pg/mL, T-tau > 450 pg/mL, p-tau181 > 62 
8 
  
pg/mL for the CSF sampels measured after 06/2012; at Mölndal Clinical Neurochemistry 
Laboratory, Aβ1-42 < 550 pg/mL, T-tau > 400 pg/mL, p-tau181 > 80 pg/mL.  
 
2.1.5 Immunoassay for YKL-40 
All CSF YKL-40 analyses were performed at the Clinical Neurochemistry Laboratory at the 
Sahlgrenska University Hospital, Mölndal, Sweden, using a commercial available ELISA kit 
(R&D Systems, Minneapolis, MN, US), according to manufacturer instructions. The 
measurements were performed in one round of experiments using one batch of reagents by 
board-certified laboratory technicians who were blinded to clinical data. Intra-assay coefficients 
of variation were below 10%. All samples were well within the linear range of the assay.  
 
2.1.6 Statistical Analysis  
Associations between sex and diagnostic group were assessed by Fisher's exact test, and the 
associations between age and diagnostic group was assessed through a nonparametric Kruskal-
Wallis (KW) test. Subsequently, as a preprocessing step, all YKL-40 values were adjusted for 
age, sex and site employing nonparametric regression to enable age-,sex- and site- independent 
assessment of the diagnostic potential of YKL-40 while foregoing assumptions of normality. We 
conducted group-wise comparisons of YKL-40 values through nonparametric KW tests followed 
by pairwise post-hoc comparison (Conover's-test for multiple comparisons) whenever the result 
of the KW test was statistically significant (p<0.05). Results of post-hoc testing were corrected 
for multiple comparisons using a False Discovery Rate (FDR) procedure (α=0.05).  
We then evaluated the diagnostic potential of YKL-40 using logistic regression within a leave-
one out cross validation (LOO-CV) approach in the following a priori comparisons: HC vs. AD 
and AD vs. FTD (Level I), HC vs. group 3 [A-/T±/N+ or A-/T+/N±], HC vs. group 4 [A+/T-/N-
], HC vs. group 5 [A+/T±/N+ or A+/T+/N±] (Level II). In this analysis, the age-, sex-, and site 
adjusted YKL-40 values were entered as predictors and the diagnostic group was entered as the 
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dependent variable. After model fitting, we calculated the area under the receiver operating 
characteristic curve (AUROC) and its associated confidence intervals using a bootstrap 
procedure (100000 bootstraps) [37] by pooling predictions computed on the test sets from each 
train-test split in the LOO-CV procedure. The discriminatory ability of YKL-40 to correctly 
allocate participants to diagnostic groups was classified as follows: excellent (AUROC 0.90-
1.00), good (AUROC 0.80-0.89), fair (AUROC 0.70-0.79), poor (AUROC 0.60-0.69), or fail/no 
discriminatory capacity (AUROC 0.50-0.59) [38]. 
All statistical analyses were performed in the R statistical environment version 3.2.3 
(available at https://www.R-project.org/) under a Linux environment using the nonparametric 
kernel smoothing methods for mixed data types package (np package) [39], partial ROC (pROC) 
package [37], and the pairwise multiple comparison of mean ranks (PMCMR) package [38]. 
Two-tailed P values < 0.05 were considered statistically significant. 
 
3.1 RESULTS 
 
3.1.2 CSF YKL-40 levels in the population categorized according to Level I 
Table 1 summarizes the levels of all analytes, combined with the demographic and clinical 
data of the population classified in line with Level I classification. Cognitively HC were slightly 
but significantly younger than MCI, AD, and FTD patients. MMSE scores were significantly 
lower in AD compared with cognitively HC and MCI. Compared with HCs group, CSF YKL-40 
levels were significantly increased in AD (P=0.032) and FTD (P=0.049) (Figure 2A).  
 
3.1.3 CSF YKL-40 levels in the population categorized according to Level II 
Table 2 summarizes the levels of all analytes, combined with the demographic and clinical 
data of the population classified in line with Level II criteria. Cognitively HC (group 1) and 
patients belonging to group 2 [A-T-N-] were significantly younger than all the other groups 
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(Table 1). Compared with group 1 (HC), CSF YKL-40 levels were significantly increased in 
group 3 [A-/T±/N+ or A-/T+/N±] (P= 0.002), and group 5 [A+/T±/N+ or A+/T+/N±] (P= 0.002). 
Group 3 [A-/T±/N+ or A-/T+/N±], and group 5 [A+/T±/N+ or A+/T+/N±] patients presented 
substantially higher CSF YKL-40 concentrations compared with group 4 [A+/T-/N-] (P< 0.001 
for both) patients, and compared with cases belonging to the FTD group (P=0.006 and P=0.007, 
respectively); group 3 [A-/T±/N+ or A-/T+/N±] patients presented higher CSF YKL-40 
concentrations compared to group 2 [A-/T-/N-] patients (P=0.033), (Figure 2B). 
 
3.1.4 Diagnostic value of CSF YKL-40 in the population at Level I  
We found that YKL-40 differentiated HC from AD patients with an AUROC of 0.69 (95% 
CI, 0.55-0.84) (Figure 3A). CSF YKL-40 discriminated AD from FTD patients with an AUROC 
of 0.71 (95% CI, 0.51-0.91) (Figure 3B) . 
 
3.1.5 Discriminative value of CSF YKL-40 in the population at Level II  
CSF YKL-40 discriminated cognitively HC from the group 3 [A-/T±/N+ or A-/T+/N±], group 
4 [A-/T±/N+ or A-/T+/N±], group 5 [A+/T±/N+ or A+/T+/N±] with AUROCs=0.76, (95% CI, 
0.58-0.94), 0.52 (95% CI, 0.29-0.74), and 0.72 (95% CI, 0.58-0.87) (Figure 4A-C), respectively. 
CSF YKL-40 differentiated group 5 [A+/T±/N+ or A+/T+/N±] from the FTD with AUROC= 
0.73 (95% CI, 0.54-0.92) (Figure 4D).  
 
 
4.1 DISCUSSION 
 
In Level I, CSF YKL-40 concentrations were significantly increased in clinically 
diagnosed AD patients compared with HC (Figure 2A). Moreover, the corresponding AUROC 
was poor/borderline fair in discriminating the two groups (Figure 3A). These findings partly 
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confirmed previous studies [16,18,20,25,26,28] and also the data from a recent meta-analysis 
[14]; in contrast, one study showed no differences between AD and HC [22]. Importantly, AD 
patients showed higher levels of CSF YKL-40 when compared to FTD; indeed, CSF YKL-40 
gives a fair performance in distinguishing between the two groups (Figure 3B). In the literature, 
very few studies evaluated the diagnostic accuracy of CSF YKL-40 in discriminating between 
AD and FTD patients, and these studies reported conflicting results. In particular, Craig-Shapiro 
and colleagues reported higher levels of CSF YKL-40 in FTD compared to mild AD [18]; 
conversely, two other studies found no significant differences between AD and FTD [15,19].  
Level II analysis showed that CSF YKL-40 concentrations were significantly increased in 
patients which were tau-positive only and those with AD pathology compared to HC (group 1) 
(Figure 2B). We found that YKL-40 delivered fair performance in discriminating tau-positive 
and AD pathology patients from HC (Figure 4A and 4C), but not in discriminating Aβ-positive 
only patients from HC (Figure 4B). These results generally agree with currently available 
studies which point toward the idea that CSF YKL-40 concentrations are more related to tau 
protein pathology as opposed to Aβ pathology [15,17,19,20,23,24]. Tau-positive patients 
revealed higher CSF concentrations of YKL-40 compared to patients with non-AD pathology, 
patients which were Aβ-positive only, and FTD patients. Similarly, AD pathology patients 
showed higher CSF levels of YKL-40 compared with patients which were Aβ-positive only, 
FTD patients, and a trend towards higher levels of YKL-40 in comparison to non-AD pathology 
patients. In particular, the AUROCs related to discriminating between AD pathology patients 
and FTD was fair (Figure 4D), i.e. comparable to what we found in Level I analysis. Several 
explanations support the fact that FTD patients can display lower CSF YKL-40 levels when 
compared to AD patients. In particular, FTD patients may have an underlying neurodegenerative 
process not related to tau protein [40]. This pathological variability possibly reflects the common 
clinical finding that FTD is a heterogeneous syndrome with different and overlapping 
phenotypes.  
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CSF YKL-40 can be considered as a biomarker of a specific pathogenic mechanism, 
allowing for in vivo measurement of neuroinflammatory processes that may be complementary 
to the core AD CSF biomarkers Aβ1-42, T-tau and p-tau. The importance of having an early 
biomarker of neuroinflammation in AD is intriguing not only for diagnostic purposes 
(neuroinflammation is probably involved in other, additional neurodegenerative diseases [41]) 
but also because it can be predictive of response to novel anti-inflammatory drugs. In fact, 
epidemiological studies indicate that non-steroidal anti-inflammatory drugs (NSAIDs) may 
lower the risk of AD [42,43], although a number of trials reported negative results [9]. However, 
anti-inflammatory treatments may not be efficacious when administered during the dementia 
stage of AD. Notably, the naproxen trial in AD initially reported negative results; conversely, 
longer-term follow-up results suggested that naproxen may exert a protective role in 
asymptomatic subjects at baseline, thus reducing the conversion rate to AD [44,45]. The 
discovery and validation of a reliable inflammatory biomarker in prodromal AD as well as in 
preclinical phases, with the aim of tracking the response to an anti-inflammatory drug, might 
therefore represent an innovative step in developing novel therapeutic strategies for AD. 
Our study represents the first attempt to apply YKL-40 as a diagnostic CSF biomarker for 
AD following a new unbiased biomarker-based classification [4]. Some limitations needs to be 
mentioned. First, in Level II, the categorization of our patients was based on CSF biomarkers 
only - i.e. the A/T/N system was used without considering neuroimaging markers. Also, this is a 
cross-sectional study and longitudinal data are not available. In particular, we are not able to 
differentiate potentially stable MCI patients from MCI patients converting to dementia, or to 
provide data about the possible different prognosis and rate of cognitive impairment progression. 
Furthermore, the diagnosis of MCI was made in a clinical setting and extensive and/or 
homogeneous psychometric data were not available. Additionally, given the relatively low 
number of patients, we did not test the CSF YKL-40 levels in all possible (eight) categories 
reported in the classification by Jack and colleagues [4]; we merged MCI patients with those in 
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the dementia stage of AD on the basis of core biomarkers assessment, without considering the 
degree of severity of cognitive impairment. However, the clinical distinction between MCI and 
dementia is not clear and time dependent; in this regard, the IWG-2 criteria consider MCI 
patients with AD pathology as AD in its prodromal phase [7]. Finally, with the exception of 
YKL-40, the measurements of the CSF core AD biomarkers, were performed in different 
laboratories and, while we controlled for center effects in our statistical analysis, additional inter-
laboratory variability cannot be completely ruled out.  
In conclusion, our study indicated that YKL-40 is poor/borderline fair and, therefore, it 
might not be able to satisfactorily differentiate AD from cognitively HC based only a purely 
clinical level of categorization. CSF YKL-40 deliveres a fair performance in discriminating 
between clinical AD and FTD. Based on core biomarker classification, CSF YKL-40 levels 
fairly distinguished HC individuals from cognitive impaired patients with both Aβ and tau 
pathology and cognitively impaired patients with tau pathology only, and both Aβ and tau 
pathology patients from FTD. In contrast, CSF YKL-40 levels were not useful in distinguishing 
between HC and cognitively impaired patients who were Aβ-positive only. Overall, CSF YKL-
40 does not seem to play a major role in distinguishing clinical AD and AD pathology patients 
from HC subjects or from  FTD cases. However, our results confirm that CSF YKL-40 levels 
should be considered a biomarker of neuroinflammation potentially related to neurodegenerative 
processes associated with tau protein. 
We believe that, in the future, large longitudinal studies will be able to investigate the AD 
spectrum by applying the unbiased A/T/N classification system which can be considered an 
adaptive and flexible “open source” approach, based on a pattern of established biomarkers 
which however, can be potentially expanded to integrate novel biological biomarkers, genetic 
and epigenetic factors [46] as well as, possibly, indicators spanning different dimensions of 
pathology such as MRI-derived grey matter atrophy or functionally relevant burden of white 
matter damage [47].  
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